Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age: results with 5 years of follow-up for the RESONATE-2 study Tedeschi, A., Burger, J. A., Barr, P., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, X., Lal, I., Dean, J., Kipps, T. J. TAYLOR & FRANCIS LTD. 2020: 38–40
View details for Web of Science ID 000534385400028